Abstract
The prevalence of obesity and atherosclerosis has substantially increased worldwide over the past several decades. Peroxisome proliferator-activated receptors (PPARs), as fatty acids sensors, have been therapeutic targets in several human lipid metabolic diseases, such as obesity, atherosclerosis, diabetes, hyperlipidaemia, and non-alcoholic fatty liver disease. Constitutive androstane receptor (CAR) and liver X receptors (LXRs) were also reported as potential therapeutic targets for the treatment of obesity and atherosclerosis, respectively. Further clarification of the internal relationships between these three lipid metabolic nuclear receptors is necessary to enable drug discovery. In this review, we mainly summarized the cross-talk of PPARs-CAR in obesity and PPARs-LXRs in atherosclerosis.
Highlights
Obesity is a lipid metabolic disturbance that has been growing across the world for nearly half a century
Genomic studies have indicated that PPARα, as a master regulator of lipid metabolism, has various target genes; the classical genes include acyl-CoA oxidase, thiolase, fatty acid transport protein (FATP), carnitine palmitoyltransferase I (CPT1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [20,22]
We reported that activation of Constitutive androstane receptor (CAR) inhibited lipogenesis by suppressing liver X receptors (LXRs) ligand-responded recruitment of LXR to the LXR response element (LXRE) and the expression of LXR target genes, whereas activation of LXR inhibited the CAR ligand-induced recruitment of CAR to Cyp2b10 [74]
Summary
Obesity is a lipid metabolic disturbance that has been growing across the world for nearly half a century. Sci. 2018, 19, 1260 been identified: PPARα (NR1C1, encoded by PPARA), PPARβ/δ (NR1C2, encoded by PPARD), and PPARγ (NR1C3, encoded by PPARG) They are all lipid sensors that transcriptionally regulate diverse aspects in response to nutritional inputs, and serving as effective therapeutic targets for some types of lipid metabolic syndrome, including obesity, atherosclerosis, dyslipidaemia, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD) [12,18]. Genomic studies have indicated that PPARα, as a master regulator of lipid metabolism, has various target genes; the classical genes include acyl-CoA oxidase, thiolase, fatty acid transport protein (FATP), carnitine palmitoyltransferase I (CPT1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [20,22]. AAlltthhoouugghh CCAARR iiss aa ppootteennttiiaall tthheerraappeeuuttiicc ttaarrggeett ffoorr lliippiidd mmeettaabboolliicc ddiisseeaassee,, ssoommee bbaarrrriieerrss eexxiisstt ffoorr tthhee cclliinniiccaall uussee ooff iittss aaggoonniissttss:: tthheerree aarree ccoonncceerrnnss aarroouunndd hheeppaattiicc eennllaarrggeemmeenntt aanndd ccaarrcciinnooggeenneessiiss. Better understanding of these mechanistic properties might help us overcome these barriers in the future
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.